Camillo Porta

Summary

Affiliation: University of Pavia
Country: Italy

Publications

  1. pmc Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma
    Camillo Porta
    Medical Oncology and Laboratory of Pre Clinical Oncology and Developmental Therapeutics, I R C C S San Matteo University Hospital Foundation, Pavia, Italy
    Biologics 2:601-9. 2008
  2. pmc Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies?
    Camillo Porta
    1 Oncologia Medica, Fondazione I R C C S Policlinico San Matteo, Pavia, Italy
    J Cancer 2:333-8. 2011
  3. pmc Lingual metastasis from renal cell carcinoma: a case report and literature review
    Carlo Ganini
    Medical Oncology
    Rare Tumors 4:e41. 2012
  4. ncbi A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer
    Chiara Paglino
    Medical Oncology, San Matteo University Hospital Foundation, Piazzale C Golgi, 19, 27100 Pavia, Italy
    Anticancer Res 33:4999-5004. 2013
  5. doi From the Zeno's paradoxes to novel immunotherapeutic agents for kidney cancer: moving from an era of wrong premises and conclusions to a better comprehension of immunology
    Camillo Porta
    I R C C S San Matteo University Hospital Foundation, Medical Oncology, Piazzale C Golgi 19, 27100 Pavia, Italy 39 0382 501355 39 0382 501223
    Expert Opin Biol Ther 13:813-5. 2013
  6. doi Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients
    Camillo Porta
    Medical Oncology, I R C C S San Matteo University Hospital Foundation, Pavia, Italy
    Oncology 84:115-22. 2013
  7. ncbi Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement
    C Porta
    Medical Oncology, IRCCS San Matteo University Hospital Foundation, Piazzale C Golgi 19, I 27100 Pavia, Italy
    Med Oncol 29:1896-907. 2012
  8. doi Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review
    Camillo Porta
    Medical Oncology, I R C C S San Matteo University Hospital Foundation, Piazzale C Golgi 19, I 27100 Pavia, Italy
    Crit Rev Oncol Hematol 82:323-37. 2012
  9. pmc Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial
    Camillo Porta
    IRCCS San Matteo University Hospital Foundation, Pavia, Italy
    Eur Urol 61:826-33. 2012
  10. ncbi Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VIIth Meeting of the International Mesothelioma Interest Group
    C Porta
    IRCCS San Matteo University Hospital, 27100 Pavia, Italy
    Med Lav 96:360-9. 2005

Detail Information

Publications79

  1. pmc Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma
    Camillo Porta
    Medical Oncology and Laboratory of Pre Clinical Oncology and Developmental Therapeutics, I R C C S San Matteo University Hospital Foundation, Pavia, Italy
    Biologics 2:601-9. 2008
    ..Ranpirnase may thus find its niche in combination with doxorubicin for mesothelioma as a second-line therapy, where no standard of care presently exists...
  2. pmc Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies?
    Camillo Porta
    1 Oncologia Medica, Fondazione I R C C S Policlinico San Matteo, Pavia, Italy
    J Cancer 2:333-8. 2011
    ....
  3. pmc Lingual metastasis from renal cell carcinoma: a case report and literature review
    Carlo Ganini
    Medical Oncology
    Rare Tumors 4:e41. 2012
    ....
  4. ncbi A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer
    Chiara Paglino
    Medical Oncology, San Matteo University Hospital Foundation, Piazzale C Golgi, 19, 27100 Pavia, Italy
    Anticancer Res 33:4999-5004. 2013
    ..In the present study we assessed the clinical benefit of two different sequential approaches, namely sorafenib, an inhibitor of mammalian target of rapamycin (mTORi) and sunitinib, or sunitinib (an mTORi) and sorafenib...
  5. doi From the Zeno's paradoxes to novel immunotherapeutic agents for kidney cancer: moving from an era of wrong premises and conclusions to a better comprehension of immunology
    Camillo Porta
    I R C C S San Matteo University Hospital Foundation, Medical Oncology, Piazzale C Golgi 19, 27100 Pavia, Italy 39 0382 501355 39 0382 501223
    Expert Opin Biol Ther 13:813-5. 2013
    ..From this well known paradox, it appears clearly that from wrong premises come wrong conclusions, something that for years has affected our perception of the role of immunotherapy in kidney cancer...
  6. doi Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients
    Camillo Porta
    Medical Oncology, I R C C S San Matteo University Hospital Foundation, Pavia, Italy
    Oncology 84:115-22. 2013
    ....
  7. ncbi Maximising the duration of disease control in metastatic renal cell carcinoma with targeted agents: an expert agreement
    C Porta
    Medical Oncology, IRCCS San Matteo University Hospital Foundation, Piazzale C Golgi 19, I 27100 Pavia, Italy
    Med Oncol 29:1896-907. 2012
    ..Until additional data are available, consideration of patient response and tolerability to treatment may facilitate current decision-making regarding when to switch and which treatment to switch to in real-life clinical practice...
  8. doi Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review
    Camillo Porta
    Medical Oncology, I R C C S San Matteo University Hospital Foundation, Piazzale C Golgi 19, I 27100 Pavia, Italy
    Crit Rev Oncol Hematol 82:323-37. 2012
    ..In conclusion, novel therapies used in combination or sequentially have potential to provide optimised treatment and patient outcomes in mRCC. The results from ongoing/planned trials are expected to help shape future therapy...
  9. pmc Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial
    Camillo Porta
    IRCCS San Matteo University Hospital Foundation, Pavia, Italy
    Eur Urol 61:826-33. 2012
    ..An understanding of the efficacy and safety of targeted agents in elderly patients with mRCC is essential to provide individualized therapy...
  10. ncbi Malignant mesothelioma in 2004: How advanced technology and new drugs are changing the perspectives of mesothelioma patients. Highlights from the VIIth Meeting of the International Mesothelioma Interest Group
    C Porta
    IRCCS San Matteo University Hospital, 27100 Pavia, Italy
    Med Lav 96:360-9. 2005
    ....
  11. ncbi Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer
    Camillo Porta
    Medical Oncology and Laboratory of Preclinical Oncology and Developmental Therapeutics, IRCCS San Matteo University Hospital, Piazzale Camillo Golgi, 2I 27100 Pavia, Italy
    Expert Rev Anticancer Ther 6:141-52. 2006
    ..The rationale of this treatment, its immunological and clinical results, as well as its pitfalls and perspectives, will be presented and discussed in this review...
  12. doi Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors
    Camillo Porta
    Medical Oncology and Laboratory of Pre Clinical Oncology and Developmental Therapeutics, Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia, Italy
    J Urol 182:2569-77. 2009
    ..Disturbed activation of the PI3K/Akt pathway is associated with many human malignancies. We reviewed the available literature on PI3K/Akt and PI3K/Akt targeting drugs for renal cell carcinoma...
  13. pmc Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy
    Camillo Porta
    Medical Oncology, I R C C S San Matteo University Hospital Foundation, Piazzale C, Golgi 19, 27100 Pavia, Italy
    BMC Cancer 11:105. 2011
    ..This study assessed safety and treatment patterns for these agents in a real-world clinical practice setting in Italy...
  14. doi Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib
    Camillo Porta
    Medical Oncology, I R C C S San Matteo University Hospital Foundation, Pavia I 27100, Italy
    Kidney Int 77:809-15. 2010
    ..Our study shows that serum levels of VEGF and NGAL are significant predictors of progression-free survival in patients with renal cell carcinoma treated with sunitinib...
  15. ncbi Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells
    Camillo Porta
    A Ferrata Institute of Internal Medicine and Medical Oncology, I R C C S San Matteo University Hospital, Piazzale C Golgi, I 27100 Pavia, Italy
    Anticancer Res 27:165-73. 2007
    ..Renal cell carcinoma (RCC)-induced immune dysfunction in patients at first diagnosis was investigated...
  16. ncbi Cytokine-based immunotherapy for advanced kidney cancer: past results and future perspectives in the era of molecularly targeted agents
    Camillo Porta
    Medical Oncology, I R C C S San Matteo University Hospital Foundation, Pavia, Italy
    ScientificWorldJournal 7:837-49. 2007
    ..g., the use of Interleukin-2 in patients with high CAIX expression), while new trials are ongoing to test immunotherapy in combination with molecularly targeted agents, such as Sorafenib, Sunitinib, or Bevacizumab...
  17. doi Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma
    Camillo Porta
    IRCCS San Matteo University Hospital Foundation, Pavia, Italy
    Cancer Treat Rev 36:16-23. 2010
    ..We recommend the integration of this approach into everyday clinical practice...
  18. ncbi Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma
    C Porta
    Internal Medicine and Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia, Italy
    Ann Oncol 19:353-8. 2008
    ..A large amount of evidence suggests a possible role of interleukin-6 (IL-6) in the pathogenesis of hepatocellular carcinoma (HCC)...
  19. ncbi Immunological stress in kidney cancer patients undergoing either open nephrectomy or nephron-sparing surgery: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells
    Camillo Porta
    Medical Oncology, I R C C S San Matteo University Hospital Foundation, I 27100 Pavia, Italy
    Oncol Rep 20:1511-9. 2008
    ....
  20. doi Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib
    C Porta
    Medical Oncology, IRCCS San Matteo University Hospital Foundation, Piazzale C Golgi, I 27100, Pavia, Italy
    Clin Exp Med 7:127-34. 2007
    ....
  21. ncbi Sorafenib tosylate in advanced kidney cancer: past, present and future
    Camillo Porta
    Medical Oncology and Laboratory of Pre Clinical Oncology and Developmental Therapeutics, IRCCS San Matteo University Hospital, Piazzale C Golgi, Pavia, Italy
    Anticancer Drugs 20:409-15. 2009
    ....
  22. ncbi Is immunotherapy re-entering the kidney cancer arena from the back door? Considerations from the Phase I/II study of siltuximab
    Camillo Porta
    Medical Oncology, IRCCS San Matteo University Hospital Foundation, Pavia, Italy
    Immunotherapy 3:487-90. 2011
    ..Furthermore, it is now clear that monoclonal antibodies actively interact with the immune system and show significant immune-modulating effects per se. Further translation research on this issue is much needed...
  23. doi Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma
    Camillo Porta
    IRCCS San Matteo University Hospital Foundation, Pavia, Italy
    Eur J Cancer 47:1287-98. 2011
    ..Safety data from RECORD-1 were reviewed by these clinicians, all of whom had experience using everolimus in patients with mRCC. Adverse events discussed were non-infectious pneumonitis, infections, stomatitis and metabolic abnormalities...
  24. doi Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases
    Camillo Porta
    IRCCS San Matteo University Hospital Foundation, Pavia, Italy
    BJU Int 108:E250-7. 2011
    ..To conduct a retrospective, multicentre, cohort analysis to assess the sequential use of the tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib...
  25. ncbi Amifostine, a reactive oxigen species scavenger with radiation- and chemo-protective properties, inhibits in vitro platelet activation induced by ADP, collagen or PAF
    C Porta
    Medicina Interna ed Oncologia Medica, Universita degli Studi di Pavia, IRCCS Policlinico San Matteo, 27100 Pavia, Italy
    Haematologica 85:820-5. 2000
    ....
  26. ncbi Sequential intrahepatic and systemic fluoropyrimidine-based chemotherapy for metastatic colorectal cancer confined to the liver. A phase II study
    C Porta
    Medicina Interna ed Oncologia Medica A Ferrata, I R C C S Policlinico San Matteo and Università degli Studi di Pavia, I 27100 Pavia, Italy
    Cancer Chemother Pharmacol 47:423-8. 2001
    ..We report our experience of combined hepatic intraarterial and systemic chemotherapy in advanced colorectal cancer patients...
  27. ncbi Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?
    Camillo Porta
    Internal Medicine and Medical Oncology, IRCCS San Matteo University Hospital, I 27100 Pavia, Italy
    Lung Cancer 38:159-62. 2002
    ....
  28. doi The European Multidisciplinary Cancer Congress (ECCO 16, ESMO 36 and ESTRO 30)
    Camillo Porta
    Medical Oncology, I R C C S San Matteo University Hospital Foundation, 19 Piazzale C Golgi, 27100 Pavia, Italy
    Future Oncol 8:13-5. 2012
    ..Integrating basic and translational science, surgery, radiotherapy, medical oncology, and care" was the mission statement of the 2011 European Multidisciplinary Cancer Congress, which was held in Stockholm, Sweden, on 23-27 September 2011...
  29. ncbi Impaired bone marrow hematopoietic progenitor cell function in rheumatoid arthritis patients candidated to autologous hematopoietic stem cell transplantation
    C Porta
    Istituto di Medicina Interna ed Oncologia Medica, Università degli Studi di Pavia e I R C C S Policlinico San Matteo, Pavia, Italy
    Bone Marrow Transplant 33:721-8. 2004
    ..These observations may identify the biological risk factors for impaired mobilization and/or engraftment when RA patients are candidates for autologous hematopoietic stem cell grafting...
  30. ncbi Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study
    Camillo Porta
    Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientificio San Matteo University Hospital, Pavia, Italy
    Cancer 100:2132-8. 2004
    ..In the current Phase II study, the authors explored the antitumor activity of a combination of gemcitabine and oxaliplatin (L-OHP) in this setting...
  31. ncbi Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patients
    Camillo Porta
    Medical Oncology, I R C C S San Matteo University Hospital, Piazzale C Golgi, I 27100 Pavia, Italy
    Oncol Rep 13:689-95. 2005
    ....
  32. ncbi Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients
    Camillo Porta
    Medical Oncology, I R C C S San Matteo University Hospital, Piazzale C Golgi, I 27100 Pavia, Italy
    Lung Cancer 48:429-34. 2005
    ..57%), while the other 10 patients (71.42%) progressed despite treatment. Median time to progression (TTP) was 8 weeks (average: 9.85, range: 7-20), while median overall survival was just 14 weeks (average: 21.69, range: 9-66+)...
  33. ncbi Autoimmunity in thrombotic thrombocytopenic purpura
    Camillo Porta
    A Ferrata Institute of Internal Medicine and Medical Oncology, I R C C S San Matteo University Hospital, Pavia, Italy
    Semin Thromb Hemost 31:633-40. 2005
    ....
  34. ncbi Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor
    Silvia Ferrari
    Flow Cytometry and Cell Therapy Unit, IRCCS San Matteo University Hospital, 27100 Pavia, Italy
    Cancer Immunol Immunother 52:359-66. 2003
    ..The aim of this study was to evaluate the effect on DC release and on their subsets of three regimens utilized to mobilize CD34+ cells into the PB in cancer patients and in normal CD34+ cell donors...
  35. doi Tolerability of first-line therapy for metastatic renal cell carcinoma
    Camillo Porta
    Medical Oncology, IRCCS San Matteo University Hospital Foundation, Piazzale C Golgi 19, I 27100 Pavia, Italy
    Cancer Treat Rev 35:297-307. 2009
    ..Finally, the implications of the tolerability profiles of these agents for combination therapy and use in broader populations than those enrolled in trials are assessed...
  36. ncbi Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis
    Elisa Ferraris
    Oncologia Medica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
    Tumori 95:542-4. 2009
    ..However, patients must be carefully selected and monitored, since sorafenib administration unquestionably increases the risk of side effects in patients affected by several conditions...
  37. ncbi The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma
    Ilaria Imarisio
    Medical Oncology, IRCCS San Matteo University Hospital Foundation, Piazzale Camillo Golgi 19, 27100 Pavia, Italy
    Future Oncol 8:1051-7. 2012
    ..To evaluate the effect of sorafenib on the glucose tolerance and diabetic status of patients with metastatic renal cell carcinoma (RCC) or advanced hepatocellular carcinoma (HCC)...
  38. doi Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study
    Chiara Paglino
    Medical Oncology, IRCCS San Matteo University Hospital Foundation, Piazzale C Golgi 19, Pavia, I 27100 Pavia, Italy
    Future Oncol 8:1605-12. 2012
    ..Here, our experience in patients with non-clear cell kidney cancer treated as part of the sunitinib Expanded Access Program is reported...
  39. ncbi Flow cytometric analysis of circulating dendritic cell subsets and intracellular cytokine production in advanced breast cancer patients
    Silvia Ferrari
    Flow Cytometry and Cell Therapy Unit, Medical Oncology, IRCCS San Matteo University Hospital, 2, P le Golgi, 27100 Pavia, Italy
    Oncol Rep 14:113-20. 2005
    ....
  40. doi Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science
    Camillo Porta
    Medical Oncology, IRCCS, San Matteo University Hospital Foundation, Piazzale C Golgi, 19, I 27100 Pavia, Italy
    Expert Rev Anticancer Ther 12:1571-7. 2012
    ....
  41. doi Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma
    Giuseppe Procopio
    Department of Medical Oncology, Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G Veneziani 1, 20133 Milan, Italy
    Expert Rev Anticancer Ther 12:1089-96. 2012
    ....
  42. pmc Concurrent intra-arterial carboplatin administration and radiation therapy for the treatment of advanced head and neck squamous cell carcinoma: short term results
    Giulia Bertino
    Department of Otolaryngology Head Neck Surgery, University of Pavia, IRCCS Policlinico S, Matteo Foundation, P le Golgi 2, 27100 Pavia, Italy
    BMC Cancer 9:313. 2009
    ..The aim of the present study was to evaluate the survival, efficacy and safety of a modified RADPLAT-like protocol using carboplatin instead of cisplatin...
  43. ncbi Weekly taxanes in metastatic breast cancer (review)
    Matteo Zimatore
    Medicina Interna e Oncologia Medica, Università e IRCCS Policlinico San Matteo, I 27100 Pavia, Italy
    Oncol Rep 9:1047-52. 2002
    ..Ongoing phase III trials will clarify the efficacy of the weekly administration schedules and will define their role in the treatment of the metastatic breast cancer...
  44. ncbi Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients
    Andrea Sartore-Bianchi
    Medical Oncology, I R C C S San Matteo University Hospital, I 27100 Pavia, Italy
    Oncol Rep 12:855-9. 2004
    ....
  45. doi Surgery and target agents for renal cell carcinoma treatment: the path between proper interaction
    Carlo Ganini
    Medical Oncology, I R C C S San Matteo University Hospital Foundation, Piazzale C Golgi 19, Pavia, Italy
    Urologia 78:9-15. 2011
    ..Once an orphan disease, it has undergone an impressive change in its natural history with an improvement in overall survival, thanks to the development of new target agents...
  46. ncbi Impact of topotecan-based chemotherapy on the immune system of advanced ovarian cancer patients: an immunophenotypic study
    Silvia Ferrari
    Flow Cytometry and Cell Therapy Unit, Medical Oncology, I R C C S San Matteo University Hospital, Pavia, Italy
    Oncol Rep 9:1107-13. 2002
    ..This information should be considered when utilizing topotecan with other anticancer drugs in the adjuvant setting as well as when dose-intensification of topotecan with stem cell support is planned...
  47. ncbi Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II study
    Mario Airoldi
    Department of Medical Oncology, San Giovanni Antica Sede Hospital, Torino, Italy
    Am J Clin Oncol 27:155-63. 2004
    ..The concurrent administration of two drugs does not alter pharmacokinetic drug behavior compared with single-agent data...
  48. ncbi A rapid D-dimer assay in patients presenting at the emergency room with suspected acute venous thrombosis: accuracy and relation to clinical variables
    S Siragusa
    Servizio Pronto Soccorso ed Accettazione, IRCCS Policlinico S Matteo, Piazzale Golgi 2, 27100 Pavia, Italy
    Haematologica 86:856-61. 2001
    ....
  49. ncbi Strategies of medical treatment for metastatic breast cancer (Review)
    M Danova
    Flow Cytometry and Cell Therapy Unit, IRCCS San Matteo University Hospital, I 27100 Pavia, Italy
    Int J Oncol 19:733-9. 2001
    ..Moreover, the present trend is to try to rationalize the therapeutic approach on the basis of biological parameters which are prognostic and predictive of treatment response...
  50. ncbi Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol
    A Riccardi
    Medicina Interna e Oncologia Medica, Universita and Istituto di Ricovero e Cura a Carattere Scientifico Policlinico S Matteo, 27100 Pavia, Italy
    Eur J Cancer 39:31-7. 2003
    ..These data indicate that patients who maintain SD during first-line chemotherapy have a prognosis similar to that of patients who attain a response. Only patients whose disease progresses have a distinctly worse outcome...
  51. pmc Natural history of malignant bone disease in renal cancer: final results of an italian bone metastasis survey
    Daniele Santini
    Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
    PLoS ONE 8:e83026. 2013
    ..Bone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC...
  52. pmc Store-operated Ca2+ entry is remodelled and controls in vitro angiogenesis in endothelial progenitor cells isolated from tumoral patients
    Francesco Lodola
    Department of Biology and Biotechnology Lazzaro Spallanzani, University of Pavia, Pavia, Italy
    PLoS ONE 7:e42541. 2012
    ..As oncogenesis may be associated to the capability of tumor cells to grow independently on Ca(2+) influx, it is important to assess whether SOCE regulates EPC-dependent angiogenesis also in tumor patients...
  53. ncbi 3rd Pavia international symposium on advanced kidney cancer
    Camillo Porta
    I R C C S San Matteo University Hospital Foundation, Medical Oncology, 27100 Pavia, Italy
    Expert Opin Pharmacother 13:445-53. 2012
    ....
  54. ncbi Sigmoid colon metastasis from sarcomatoid renal cell carcinoma
    Roberta Invernizzi
    Department of Medical Oncology, IRCCS San Matteo University Hospital, Pavia, Italy
    Tumori 92:246-8. 2006
    ..Computed tomography showed marked disease progression and the patient died 3 weeks later. Sigmoid colon metastasis from a primary sarcomatoid renal cell carcinoma has never been described in the literature...
  55. ncbi In vitro antioxidant properties of amifostine (WR-2721, Ethyol)
    F Marzatico
    Universita degli Studi di Pavia, Dipartimento di Scienze Fisiologiche e Farmacologiche Cellulari e Molecolari, Sezione di Farmacologia e Biotecnologie Farmacologiche, Piazza Botta, 11, I 27100 Pavia, Italy
    Cancer Chemother Pharmacol 45:172-6. 2000
    ..Despite a growing number of reports strongly supporting amifostine's clinical efficacy, few authors have focused on the biochemical basis of amifostine's antioxidant activity...
  56. pmc Store-operated ca(2+) entry does not control proliferation in primary cultures of human metastatic renal cellular carcinoma
    Silvia Dragoni
    Department of Biology and Biotechnology Lazzaro Spallanzani, University of Pavia, Via Forlanini 6, 27100 Pavia, Italy
    Biomed Res Int 2014:739494. 2014
    ..Consistently, no detectable Ca(2+) signal was elicited by growth factor stimulation. Therefore, a functional SOCE is expressed but does not control proliferation of mRCC cells isolated from patients resistant to multikinase inhibitors. ..
  57. ncbi Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents
    Francesco Massari
    Department of Medical Oncology, G B Rossi Academic Hospital, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy
    Clin Genitourin Cancer 11:471-6. 2013
    ..Although data from ongoing trials with targeted agents are awaited, we used a meta-analytical approach to explore whether cytokines (CK), vaccines (VAX), or other therapies may differentially influence patients' outcomes...
  58. ncbi Orai1 and Transient Receptor Potential Channels as Novel Molecular Targets to Impair Tumor Neovascularization in Renal Cell Carcinoma and other Malignancies
    Francesco Moccia
    Laboratory of Physiology, Department of Biology and Biotechnology Lazzaro Spallanzani, University of Pavia, Via Forlanini 6, 27100, Pavia, Italy
    Anticancer Agents Med Chem 14:296-312. 2014
    ..As a consequence, TRP channels and Orai1 might serve as novel molecular targets to develop alternative and more effective strategies of angiogenesis inhibition. ..
  59. pmc Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients
    Daniele Santini
    Department of Medical Oncology, University Campus Bio Medico of Rome, Rome, Italy
    PLoS ONE 6:e19234. 2011
    ..RANKL stimulates migration of RANK-expressing tumor cells in vitro, conversely inhibited by OPG...
  60. ncbi Determination of free and total (free plus protein-bound) melatonin in plasma and cerebrospinal fluid by high-performance liquid chromatography with fluorescence detection
    Vittoria Rizzo
    Dipartimento di Biochimica, Sezione Analisi Chimico Cliniche, IRRCS Policlinico San Matteo, Universita degli Studi di Pavia, 27100 Pavia, Italy
    J Chromatogr B Analyt Technol Biomed Life Sci 774:17-24. 2002
    ..23+/-2.22 and 7.40+/-5.68 pg/ml, respectively. Detection of MLT in CSF was 5.01+/-2.31 and 28.55+/-6.95 pg/ml for the free and total fraction, respectively...
  61. ncbi Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering
    Ana I Romero
    Authors Affiliations Cancer Institute Gustave Roussy Departments of Epidemiology and Statistics and Dermatology Stabilité génétique et oncogenèse UMR 8200 Clinical Oncology, Melanoma Branch, Cancer Institute Gustave Roussy Department of BioPathology, Translational Research Laboratory and Biobank, Institute Gustave Roussy Institut National de la Santé et de la Recherche Medicale INSERM, U1015 Center of Clinical Investigations CBT507, Biotherapy, Villejuif INSERM U1102, institut de cancérologie de l Ouest, Saint Herblain INSERM, U892, Institut de Recherche Therapeutique, Nantes INSERM, U1016, Saint Vincent de Paul Hospital INSERM U1016, CNRS UMR8104, Cochin Institute Faculté Paris Sud Université Paris XI, Paris, France and IRCCS San Matteo University Hospital Foundation, Pavia, Italy
    Cancer Res 74:68-80. 2014
    ....
  62. pmc Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib
    Camillo Porta
    Camillo Porta, Medical Oncology and Laboratory of Preclinical Oncology and Experimental Therapies, IRCCS San Matteo University Hospital Foundation, Pavia I 27100, Italy
    World J Hepatol 2:103-13. 2010
    ....
  63. ncbi Antioxidant enzymatic system and free radicals pathway in two different human cancer cell lines
    C Porta
    Istituto di Terapia Medica, Universita degli Studi di Pavia, I R C C S Policlinico San Matteo, Italy
    Anticancer Res 16:2741-7. 1996
    ..The two lines behaved differently in response to the above treatments. These observations might be important in designing more specific cancer treatments...
  64. ncbi Platelet agonists and calcium homeostasis in endothelial cells: possible role in the interaction of endothelium with hemostatic system
    C Porta
    Sezione di Medicina Interna ed Oncologia, Universita degli Studi di Pavia, IRCCS Policlinico San Matteo, Italy
    Haematologica 83:610-5. 1998
    ..We addressed the hypothesis that some platelet agonists and products of activation of the hemostatic system could determine Ca++ transients in a bovine pulmonary artery endothelial cell line (CPA-47)...
  65. pmc Cardiovascular, cerebrovascular, and respiratory changes induced by different types of music in musicians and non-musicians: the importance of silence
    L Bernardi
    Department of Internal Medicine, IRCCS S Matteo, University of Pavia, Pavia, Italy
    Heart 92:445-52. 2006
    ....
  66. ncbi SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure
    Paola Cacciotti
    Department of Medical Sciences, University of Piemonte Orientale A Avogadro, Novara, Italy
    Cancer Res 65:5256-62. 2005
    ....
  67. ncbi Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008;
    Camillo Porta
    Eur Urol 53:1092-3. 2008
  68. doi Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
    ..A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma...
  69. ncbi Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma
    Andrea Sartore-Bianchi
    Institute of Internal Medicine and Medical Oncology, IRCCS Policlinico San Matteo University Hospital, 1 27100 Pavia corrected Italy
    Clin Cancer Res 13:5942-51. 2007
    ..We aimed at verifying whether the proteasome inhibitor Bortezomib could abrogate NF-kappaB activity in MMe cells, leading to tumor cell death and may be established as a novel treatment for this aggressive neoplasm...
  70. ncbi Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II study
    Sergio Palmeri
    Department of Oncology, Division of Medical Oncology, University of Palermo, Palermo, Italy
    Cancer 107:2898-905. 2006
    ..To date, the standard treatment for patients who have carcinoma of unknown primary site has not been established...
  71. ncbi Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts
    Pietro Bertino
    Department of Chemical, Food, Pharmaceutical and Pharmacological Sciences and Drug and Food Biotechnology Center, University of Piemonte Orientale A Avogadro, Novara, Italy
    Clin Cancer Res 14:541-8. 2008
    ..We previously showed that imatinib mesylate synergizes with gemcitabine and pemetrexed in PDGFRbeta-positive mesothelioma cells. Here, we aimed at investigating these combined treatments in a novel mesothelioma model...
  72. ncbi Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin
    Robert G Gish
    California Pacific Medical Center, San Francisco, CA 94115, USA
    J Clin Oncol 25:3069-75. 2007
    ..The study objective was to compare the overall survival (OS) of patients with unresectable or metastatic hepatocellular carcinoma (HCC) treated with nolatrexed (NOL) or doxorubicin (DOX)...
  73. pmc Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed
    Pietro Bertino
    DISCAFF Department and DFBC Center, University of Piemonte Orientale A Avogadro, 28100 Novara, Italy
    Thorax 62:690-5. 2007
    ..A study was undertaken to assess whether imatinib alone or combined with chemotherapeutic agents may be effective for treating mesothelioma...
  74. ncbi The presence of simian-virus 40 sequences in mesothelioma and mesothelial cells is associated with high levels of vascular endothelial growth factor
    Paola Cacciotti
    Department of Medical Sciences, University of Piemonte Orientale A Avogadro, Novara, Italy
    Am J Respir Cell Mol Biol 26:189-93. 2002
    ..These results offer the first evidence that SV40 can cause VEGF release in SV40-positive MM cells and that entire viral genome is required for this effect...
  75. ncbi Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma
    Camillo Porta
    Cancer Chemother Pharmacol 59:149-50. 2007
  76. ncbi New agents in the management of advanced mesothelioma
    Nicholas J Vogelzang
    Nevada Cancer Institute, Las Vegas, NV 89135, USA
    Semin Oncol 32:336-50. 2005
    ..Together with the newer drugs, rapidly emerging from the laboratory to be applied in the clinic, we have the hope of making further advances in the struggle against this disease...
  77. ncbi Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone
    Maria Teresa Valle
    Servizio di Immunologia, Universita di Genova, Ospedale San Martino, Genova, Italy
    Int J Mol Med 11:161-7. 2003
    ..Even though the role of TGF-beta in the promotion of MMe growth should be further and better defined, this effect should be considered when designing new therapeutical approaches aimed at improving the immune response to MMe...
  78. ncbi Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet 372:449-56. 2008
    ..We did a phase III, randomised, double-blind, placebo-controlled trial of everolimus in patients with metastatic renal cell carcinoma whose disease had progressed on vascular endothelial growth factor-targeted therapy...